Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.81 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.81 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.81 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.81 |
| ▸ | NQO2 | P16083 | 1/20 | 0.81 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.81 |
| ▸ | ACTR2 | P61160 | 1/20 | 0.81 |
| ▸ | CCR1 | P32246 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14337968 | 1.00 | MAPK14 (0.81) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL14185090 | 1.00 | MAPK14 (0.81) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL14338083 | 1.00 | MAPK14 (0.81) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL4488337 | 0.91 | MAPK14 (0.67) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL5201401 | 0.91 | MAPK14 (0.67) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL14338034 | 0.91 | MAPK14 (0.66) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL14185108 | 0.91 | MAPK14 (0.66) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL14185105 | 0.91 | MAPK14 (0.66) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL14185123 | 0.90 | MAPK14 (0.65) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| Talmapimod SCHEMBL4779238 | 0.89 | MAPK14 (1.00) | MAPK14MAPK11MAPK13MAPK12NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2022-04-05 | — | — | US | disclosed |
| US-20200383963-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. | 2020-12-10 | — | — | US | disclosed |
| US-10342786-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20190105311-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. | 2019-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200383963-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, RHOXF2 | MAPK14 193/4885MAPK11 726/4885MAPK13 286/4885 |
| US-20190105311-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 196/4885MAPK11 866/4885MAPK13 304/4885 |
| US-10342786-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885MAPK11 857/4885MAPK13 303/4885 |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885MAPK11 857/4885MAPK13 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.